Wiley Bros. Aintree Capital, LLC Ionis Pharmaceuticals Inc Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 9,606 shares of IONS stock, worth $339,764. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,606Holding current value
$339,764% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IONS
# of Institutions
404Shares Held
136MCall Options Held
862KPut Options Held
582K-
Vanguard Group Inc Valley Forge, PA15.1MShares$533 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$501 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$365 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$309 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$279 Million5.32% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.02B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...